Michele McTigue

Michele McTigue

UNVERIFIED PROFILE

Are you Michele McTigue?   Register this Author

Register author
Michele McTigue

Michele McTigue

Publications by authors named "Michele McTigue"

Are you Michele McTigue?   Register this Author

19Publications

891Reads

24Profile Views

Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase.

ACS Med Chem Lett 2018 Sep 24;9(9):872-877. Epub 2018 Aug 24.

Pfizer Worldwide Research and Development, La Jolla Oncology, 10770 Science Center Drive, San Diego, California 92121, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.8b00348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142052PMC
September 2018

Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib.

ACS Med Chem Lett 2018 Sep 18;9(9):878-883. Epub 2018 Jun 18.

Oncology Medicinal Sciences, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.8b00147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142050PMC
September 2018

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

N Engl J Med 2016 Jan 23;374(1):54-61. Epub 2015 Dec 23.

Massachusetts General Hospital Cancer Center (A.T.S., L.F., J.F.G., L.D., R.L.F., K.R.S., J.L., G.G., J.A.E.) and the Department of Pathology (A.J.I., L.L., G.G.), Massachusetts General Hospital, Boston, and the Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge (I.L., G.G.) - all in Massachusetts; Pfizer Worldwide Research and Development, La Jolla, CA (S.B., A.B., B.J.B., Y.-L.D., W.L., L.P.J., T.S., S.T., M.M., T.W.J.); and the Japanese Foundation for Cancer Research, Tokyo (R.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1508887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773904PMC
January 2016

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors.

Proc Natl Acad Sci U S A 2012 Nov 17;109(45):18281-9. Epub 2012 Sep 17.

Department of Oncology Medicinal Chemistry, Pfizer Worldwide Research and Development, Pfizer Inc., San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1207759109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494931PMC
November 2012

Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib.

Biochemistry 2009 Jul;48(29):7019-31

Pfizer Global Research and Development, La Jolla, Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi900522yDOI Listing
July 2009

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

Biochemistry 2009 Jun;48(23):5339-49

Pfizer Global Research and Development, La Jolla, Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi900438wDOI Listing
June 2009